188 related articles for article (PubMed ID: 36241147)
1. Successful Generation of CD19 Chimeric Antigen Receptor T Cells from Patients with Advanced Systemic Lupus Erythematosus.
Kretschmann S; Völkl S; Reimann H; Krönke G; Schett G; Achenbach S; Lutzny-Geier G; Müller F; Mougiakakos D; Dingfelder J; Flamann C; Hanssens L; Gary R; Mackensen A; Aigner M
Transplant Cell Ther; 2023 Jan; 29(1):27-33. PubMed ID: 36241147
[TBL] [Abstract][Full Text] [Related]
2. Fully Human Anti-CD19 CAR T Cells Derived from Systemic Lupus Erythematosus Patients Exhibit Cytotoxicity with Reduced Inflammatory Cytokine Production.
Dingfelder J; Aigner M; Taubmann J; Minopoulou I; Park S; Kaplan CD; Cheng JK; Van Blarcom T; Schett G; Mackensen A; Lutzny-Geier G
Transplant Cell Ther; 2024 Jun; 30(6):582.e1-582.e10. PubMed ID: 38548226
[TBL] [Abstract][Full Text] [Related]
3. Autologous CD19-Targeted Chimeric Antigen Receptor (CAR)T-Cells as the Future of Systemic Lupus Erythematosus Treatment.
Kambayana G; Surya Rini S
Curr Rheumatol Rev; 2023 Jun; 19(3):260-269. PubMed ID: 36786138
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus.
Mackensen A; Müller F; Mougiakakos D; Böltz S; Wilhelm A; Aigner M; Völkl S; Simon D; Kleyer A; Munoz L; Kretschmann S; Kharboutli S; Gary R; Reimann H; Rösler W; Uderhardt S; Bang H; Herrmann M; Ekici AB; Buettner C; Habenicht KM; Winkler TH; Krönke G; Schett G
Nat Med; 2022 Oct; 28(10):2124-2132. PubMed ID: 36109639
[TBL] [Abstract][Full Text] [Related]
5. Journal Club: Anti-CD19 Chimeric Antigen Receptor T Cell Therapy for Refractory Systemic Lupus Erythematosus.
Boulougoura A; Gendelman H; Surmachevska N; Kyttaris VC
ACR Open Rheumatol; 2023 Nov; 5(11):624-628. PubMed ID: 37766597
[TBL] [Abstract][Full Text] [Related]
6. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19
Teoh J; Brown LF
Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089
[TBL] [Abstract][Full Text] [Related]
7. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
[TBL] [Abstract][Full Text] [Related]
8. Media evaluation for production and expansion of anti-CD19 chimeric antigen receptor T cells.
Alnabhan R; Gaballa A; Mörk LM; Mattsson J; Uhlin M; Magalhaes I
Cytotherapy; 2018 Jul; 20(7):941-951. PubMed ID: 29859774
[TBL] [Abstract][Full Text] [Related]
9. CAR T-cell therapy in autoimmune diseases.
Schett G; Mackensen A; Mougiakakos D
Lancet; 2023 Nov; 402(10416):2034-2044. PubMed ID: 37748491
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus.
Jin X; Xu Q; Pu C; Zhu K; Lu C; Jiang Y; Xiao L; Han Y; Lu L
Cell Mol Immunol; 2021 Aug; 18(8):1896-1903. PubMed ID: 32472023
[TBL] [Abstract][Full Text] [Related]
11. Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering.
Michels KR; Sheih A; Hernandez SA; Brandes AH; Parrilla D; Irwin B; Perez AM; Ting HA; Nicolai CJ; Gervascio T; Shin S; Pankau MD; Muhonen M; Freeman J; Gould S; Getto R; Larson RP; Ryu BY; Scharenberg AM; Sullivan AM; Green S
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36918221
[TBL] [Abstract][Full Text] [Related]
12. Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19
Liu Q; Xu Y; Mou J; Tang K; Fu X; Li Y; Xing Y; Rao Q; Xing H; Tian Z; Wang M; Wang J
Cytotherapy; 2020 Oct; 22(10):552-562. PubMed ID: 32747298
[TBL] [Abstract][Full Text] [Related]
13. Identification of dual positive CD19+/CD3+ T cells in a leukapheresis product undergoing CAR transduction: a case report.
Schultz L; Patel S; Davis KL; Ramakrishna S; Sahaf B; Bhatia N; Baggott C; Erickson C; Majzner RG; Oak J; Bertaina A; Mackall C; Feldman S
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32929049
[TBL] [Abstract][Full Text] [Related]
14. Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy.
Nunez D; Patel D; Volkov J; Wong S; Vorndran Z; Müller F; Aigner M; Völkl S; Mackensen A; Schett G; Basu S
Mol Ther Methods Clin Dev; 2023 Dec; 31():101104. PubMed ID: 37744005
[TBL] [Abstract][Full Text] [Related]
15. Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
Schubert ML; Schmitt A; Sellner L; Neuber B; Kunz J; Wuchter P; Kunz A; Gern U; Michels B; Hofmann S; Hückelhoven-Krauss A; Kulozik A; Ho AD; Müller-Tidow C; Dreger P; Schmitt M
BMJ Open; 2019 May; 9(5):e026644. PubMed ID: 31110096
[TBL] [Abstract][Full Text] [Related]
16. A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count.
Wang H; Tsao ST; Gu M; Fu C; He F; Li X; Zhang M; Li N; Hu HM
J Transl Med; 2022 Dec; 20(1):608. PubMed ID: 36536403
[TBL] [Abstract][Full Text] [Related]
17. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus.
Kansal R; Richardson N; Neeli I; Khawaja S; Chamberlain D; Ghani M; Ghani QU; Balazs L; Beranova-Giorgianni S; Giorgianni F; Kochenderfer JN; Marion T; Albritton LM; Radic M
Sci Transl Med; 2019 Mar; 11(482):. PubMed ID: 30842314
[TBL] [Abstract][Full Text] [Related]
18. Development of a microfluidic cell transfection device into gene-edited CAR T cell manufacturing workflow.
Yu T; Jhita N; Shankles P; Fedanov A; Kramer N; Raikar SS; Sulchek T
Lab Chip; 2023 Nov; 23(22):4804-4820. PubMed ID: 37830228
[TBL] [Abstract][Full Text] [Related]
19. CAR T cells for treating autoimmune diseases.
Blache U; Tretbar S; Koehl U; Mougiakakos D; Fricke S
RMD Open; 2023 Nov; 9(4):. PubMed ID: 37996128
[TBL] [Abstract][Full Text] [Related]
20. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.
Ramos CA; Rouce R; Robertson CS; Reyna A; Narala N; Vyas G; Mehta B; Zhang H; Dakhova O; Carrum G; Kamble RT; Gee AP; Mei Z; Wu MF; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Savoldo B; Dotti G
Mol Ther; 2018 Dec; 26(12):2727-2737. PubMed ID: 30309819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
